# A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease

> **NCT04498182** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 369 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** AR-15512 Ophthalmic Solution
- **DRUG:** AR-15512 Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT04498182
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2021-07-17
- **Final completion:** 2021-07-17
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498182, "A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04498182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*